MAT 100
Alternative Names: Bone fracture GAM gene deliveryLatest Information Update: 26 Apr 2005
At a glance
- Originator Tissue Repair Company
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Fracture
Most Recent Events
- 15 Apr 2005 No development reported - Preclinical for Fracture in USA (unspecified route)
- 15 Apr 2005 Selective Genetics has ceased operations
- 21 Aug 2003 This compound is still in active development